The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects
|Healthy Subjects Hypomagnesemia||Dietary Supplement: Magnesium oxide Dietary Supplement: Magnesium citrate||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
|Official Title:||The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease|
- Intracellular magnesium levels will be assessed [ Time Frame: 30-day ]
- Platelet function tests [ Time Frame: 30-day ]
|Study Start Date:||January 2010|
|Study Completion Date:||March 2011|
|Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
Active Comparator: Magnesium oxide tables
Subjects will be instructed to take Magnox 520 qd
Dietary Supplement: Magnesium oxide
520 mg of elemental magnesium q.d.
Other Name: Magnox 520 TM
Active Comparator: Magnesium citrate tablets
Subjects will be instructed to take magnesium diasporal tablets t.i.d.
Dietary Supplement: Magnesium citrate
Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
Other Name: Magnesium Diasporal
Two oral preparations of magnesium are available in Israel:
- Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH, ISMANING, Germany
- Magnox 520 TM (magnesium oxide, 520 mg elemental magnesium), Naveh Pharma Ltd., Israel.
The data regarding the absorption difference between the two supplemental magnesium preparations (magnesium oxide and magnesium citrate) in humans is spare.
Primary objective: To find out the absorption of magnesium citrate compared to magnesium oxide in healthy subjects with no apparent heart disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00994006
|The Leviev Heart Center, Chaim Sheba Medical Center|
|Tel Hashomer, Ramat Gan, Israel, 52621|
|Principal Investigator:||Michael Shechter, MD, MA||The Leviev Heart Center, Sheba Medical Center|